Detalhe da pesquisa
1.
Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer.
N Engl J Med
; 389(20): 1851-1861, 2023 Nov 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-37870969
2.
Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial.
Cancer
; 128(24): 4203-4212, 2022 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36259380
3.
Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers.
Oncologist
; 2022 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35536733
4.
Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib.
BMC Cancer
; 22(1): 625, 2022 Jun 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35672677
5.
LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve RET-mutant medullary thyroid cancer.
Future Oncol
; 18(28): 3143-3150, 2022 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-35969032
6.
Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 22(8): 1126-1138, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34237250
7.
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
N Engl J Med
; 378(8): 731-739, 2018 02 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-29466156
8.
Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial.
Lancet Oncol
; 20(5): 711-718, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30922731
9.
Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer.
BMC Cancer
; 19(1): 196, 2019 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30832606
10.
Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT).
Cancer
; 124(11): 2365-2372, 2018 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29656442
11.
Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.
N Engl J Med
; 372(7): 621-30, 2015 Feb 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-25671254
12.
Vemurafenib in patients with BRAF(V600E)-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial.
Lancet Oncol
; 17(9): 1272-82, 2016 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-27460442
13.
Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer.
Cancer
; 122(24): 3856-3864, 2016 Dec 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-27525386
14.
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.
Lancet
; 384(9940): 319-28, 2014 Jul 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-24768112
15.
Real-world practice patterns and outcomes for RAI-refractory differentiated thyroid cancer.
Eur Thyroid J
; 13(1)2024 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38096102
16.
Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study.
Thyroid
; 34(3): 347-359, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38062732
17.
Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146.
J Immunother Cancer
; 12(1)2024 01 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-38242717
18.
Pralsetinib in Patients with Advanced/Metastatic Rearranged During Transfection (RET)-Altered Thyroid Cancer: Updated Efficacy and Safety Data from the ARROW Study.
Thyroid
; 34(1): 26-40, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38009200
19.
Population Pharmacokinetics and Exposure-Response Analysis for the Phase 3 COSMIC-311 Trial of Cabozantinib for Radioiodine-Refractory Differentiated Thyroid Cancer.
Clin Pharmacokinet
; 62(4): 587-598, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36869986
20.
A Phase Ib/II Study of Lenvatinib and Pembrolizumab in Advanced Endometrial Carcinoma (Study 111/KEYNOTE-146): Long-Term Efficacy and Safety Update.
J Clin Oncol
; 41(5): 974-979, 2023 02 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36608305